Cargando…

Distribution of E- and N-cadherin in subgroups of non-functioning pituitary neuroendocrine tumours

PURPOSE: Clinically non-functioning pituitary neuroendocrine tumours (NF-PitNETs) present a varying degree of aggressiveness, and reliable prognostic markers are lacking. We aimed to characterise the distribution of E- and N-cadherin in corticotroph, PIT1 and null-cell NF-PitNETs, and link it to the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Øystese, Kristin Astrid B., Casar-Borota, Olivera, Berg-Johnsen, Jon, Berg, Jens Petter, Bollerslev, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242907/ https://www.ncbi.nlm.nih.gov/pubmed/35674926 http://dx.doi.org/10.1007/s12020-022-03051-6

Ejemplares similares

FSH Levels Are Related to E-cadherin Expression and Subcellular Location in Nonfunctioning Pituitary Tumors
por: Kolnes, Anders J, et al.
Publicado: (2020)

TGFBR3L is associated with gonadotropin production in non-functioning gonadotroph pituitary neuroendocrine tumours
por: Kolnes, Anders Jensen, et al.
Publicado: (2023)

TGFBR3L—An Uncharacterised Pituitary Specific Membrane Protein Detected in the Gonadotroph Cells in Non-Neoplastic and Tumour Tissue
por: Sjöstedt, Evelina, et al.
Publicado: (2020)

Histopathological classification of non-functioning pituitary neuroendocrine tumors
por: Manojlovic-Gacic, Emilija, et al.
Publicado: (2017)

Intra-operative MRI facilitates tumour resection during trans-sphenoidal surgery for pituitary adenomas
por: Ramm-Pettersen, Jon, et al.
Publicado: (2011)

THU084 Corticotroph Tumor Type Influences Clinical Presentation In Patients With Nonfunctioning Pituitary Neuroendocrine Tumors
por: Al-Shamkhi, Nasrin, et al.
Publicado: (2023)

Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis
por: Tebani, Abdellah, et al.
Publicado: (2021)

Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment
por: Burman, Pia, et al.
Publicado: (2023)

Distinct Pattern of Endoplasmic Reticulum Protein Processing and Extracellular Matrix Proteins in Functioning and Silent Corticotroph Pituitary Adenomas
por: Eieland, Alexander K., et al.
Publicado: (2020)

Long-term control of acromegaly after pituitary surgery in South-Eastern Norway
por: Falch, Camilla M., et al.
Publicado: (2023)

Low immediate postoperative serum-cortisol nadir predicts the short-term, but not long-term, remission after pituitary surgery for Cushing’s disease
por: Ramm-Pettersen, Jon, et al.
Publicado: (2015)

Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours
por: Marques, Pedro, et al.
Publicado: (2019)

Hip Structure Analyses in Acromegaly: Decrease of Cortical Bone Thickness After Treatment: A Longitudinal Cohort Study
por: Godang, Kristin, et al.
Publicado: (2019)

Single Cell Metabolic Landscape of Pituitary Neuroendocrine Tumor Subgroups and Lineages
por: Batchu, Sai, et al.
Publicado: (2023)

Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours
por: Iacovazzo, Donato, et al.
Publicado: (2019)

Bone formation in custom-made cranioplasty: evidence of early and sustained bone development in bioceramic calcium phosphate implants. Patient series
por: Sundblom, Jimmy, et al.
Publicado: (2021)

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy
por: Rostami, Elham, et al.
Publicado: (2017)

Attenuated RORC Expression in the Presence of EMT Progression in Somatotroph Adenomas following Treatment with Somatostatin Analogs Is Associated with Poor Clinical Recovery
por: Lekva, Tove, et al.
Publicado: (2013)

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
por: Elston, Marianne S., et al.
Publicado: (2021)

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain
por: Lamas, Cristina, et al.
Publicado: (2023)

Altered neuroendocrine control and association to clinical symptoms in adolescent chronic fatigue syndrome: a cross-sectional study
por: Wyller, Vegard Bruun, et al.
Publicado: (2016)

Erratum to: Altered neuroendocrine control and association to clinical symptoms in adolescent chronic fatigue syndrome: a cross-sectional study
por: Wyller, Vegard Bruun, et al.
Publicado: (2017)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1 – molecular pathways
por: Cakir, Mehtap, et al.
Publicado: (2010)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2 – clinical implications
por: Cakir, Mehtap, et al.
Publicado: (2010)

Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours
por: Loughrey, Paul Benjamin, et al.
Publicado: (2022)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
por: Saksis, Rihards, et al.
Publicado: (2023)

Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations
por: Casar-Borota, Olivera, et al.
Publicado: (2020)

Case Report: Malignant Primary Sellar Paraganglioma With Unusual Genetic and Imaging Features
por: Stojanoski, Stefan, et al.
Publicado: (2021)

Protein Expression Profile of ACE2 in the Normal and COVID-19-Affected Human Brain
por: Lindskog, Cecilia, et al.
Publicado: (2022)

Molecular prognostic factors in small-intestinal neuroendocrine tumours
por: Samsom, K G, et al.
Publicado: (2019)

Pituitary Apoplexy in Patients with Pituitary Neuroendocrine Tumors (PitNET)
por: Gheorghe, Ana-Maria, et al.
Publicado: (2023)

Involvement of dysadherin and E-cadherin in the development of testicular tumours
por: Batistatou, A, et al.
Publicado: (2005)

PAX6 is frequently expressed in ependymal tumours and associated with prognostic relevant subgroups
por: Tabasaran, Julian, et al.
Publicado: (2022)

Pituitary Neuroendocrine Tumor: Is It Benign or Malignant?
por: Lee, Chae Heuck
Publicado: (2023)

Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial
por: Ito, Tetsuhide, et al.
Publicado: (2012)

Phosphorylation of β-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours
por: Rai, Ashutosh, et al.
Publicado: (2022)

Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor Cells
por: Oh, Jun Y., et al.
Publicado: (2022)

PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas
por: Cossu, Giulia, et al.
Publicado: (2023)

Effect of E-cadherin Expression on Hormone Production in Rat Anterior Pituitary Lactotrophs In Vitro
por: Kusumoto, Kenji, et al.
Publicado: (2010)

Adipose tissue distribution is associated with cardio-metabolic alterations in adult patients with juvenile-onset dermatomyositis
por: Marstein, Henriette S, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nd4g3luc9o0q1l3b4bkfq3jbdn